Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EL Bruton's tyrosine kinase (BTK) inhibitors
L01EL06 Tirabrutinib
D11070 Tirabrutinib hydrochloride (JAN/USAN) <JP>
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D11070 Tirabrutinib hydrochloride (JAN/USAN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG02022 BTK inhibitor
DG03266 Tirabrutinib
D11070 Tirabrutinib hydrochloride
Drug classes [BR:br08332]
Antineoplastic
DG02022 BTK inhibitor
D11070 Tirabrutinib hydrochloride
Target-based classification of drugs [BR:br08310]
Protein kinases
Non-receptor tyrosine kinases
TEC family
BTK
D11070 Tirabrutinib hydrochloride (JAN/USAN) <JP>
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11070
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11070
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG02022 BTK inhibitor
DG03266 Tirabrutinib